Sleep Apnea Treatment During Cardiac Rehabilitation of Congestive Heart Failure Patients (SATELIT-HF)

March 6, 2015 updated by: French Cardiology Society

SLEEP DISORDERED BREATHING DURING CARDIAC REHABILITATION A Study of the Improvement in Physical Performance of Patients With Heart Failure During Cardiac Rehabilitation Due to the Correction of Sleep Disordered Breathing

Sleep disordered breathing (SDB) is a frequent comorbidity for heart failure patients. Its prevalence varies according to the seriousness of the condition of the patients, but it is present in approximately 50% of patients. Screening patients for SDB and managing them by providing adapted ventilation therapy should improve their quality of life or even their prognosis. Moreover, SDB lowers nocturnal cardiovascular recovery abilities and leads to an increase in fatigability and, as a result, exercise intolerance in patients with heart failure. Physical training as part of a cardiac rehabilitation programme provides many benefits, including improving patients' exercise capacities. Our hypothesis is that adapted sleep disordered breathing therapy during rehabilitation will lead to an improvement in rehabilitation results.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Controlled, randomised, multicentre study. Patients will be assessed prior to starting the rehabilitation programme with regard to exercise tolerance parameters (cardiopulmonary exercise test, 6 minute walk test), ultrasound parameters and biological parameters (Na, Hb, BNP).

The cardiac rehabilitation programme will include education, secondary prevention and physical training components in each of the two groups. The physical training component will include a minimal "base" of activities that is identical for both groups. The nocturnal therapy device will be adapted to the type of SDB specific to each patient (central, mixed, obstructive). The randomisation will be stratified by centre according to predictive factors for performance improvement during rehabilitation.

The main objective is to evaluate the improvement in physical performance resulting from adapted ventilation on SDB compared to physical training alone in patients with heart failure.

Study Type

Interventional

Enrollment (Actual)

300

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Briis sous Forges, France, 91640
        • Centre Medical de Bligny
      • Châtillon, France, 92320
        • Clinique de Châtillon
      • Créteil, France, 94000
        • Hôpital Albert Chenevier
      • Dieulefit, France, 26220
        • Dieulefit Santé
      • Dinard, France, 35800
        • Hopital Arthur Gardiner
      • Durtol, France, 63830
        • Clinique de cardiopneumologie
      • Echirolles, France, 38130
        • Hôpital Sud - Institut de Rééducation
      • Issy-les-moulineaux, France, 92133
        • Hôpital Corentin Celton
      • Lomme, France, 59160
        • Clinique de la Mitterie
      • Marcy l'Etoile, France, 69280
        • Centre IRIS
      • Marseille, France, 13009
        • Centre Cardio-Vasculaire Valmante
      • Puilboreau, France, 17138
        • Clinique de réadaptation cardiaque Cardiocéan
      • Saint Etienne, France, 42055
        • Hôpital Nord 6
      • Saint Julien en Genevois, France, 74164
        • Hôpital Intercommunal Sud Léman Valserine
      • Saint Martin d'Aubigny, France, 50190
        • Centre William Harvey - le Haut Boscq
      • Tracy le Mont, France, 60170
        • Centre de réadaptation cardiaque Leopold Bellan
      • Vandoeuvre-les-Nancy, France, 54500
        • Institut Régional de Réadaptation
      • Vence, France, 06140
        • La Maison du Mineur
      • Yerres, France, 91330
        • Centre Hospitalier Calmette

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients who have NYHA class II to IIIb heart failure, operated or not, ischemic or not, without significant valve pathology.
  • Referred to cardiac rehabilitation
  • With an EF < 40%
  • And an apnea-hypopnea index > 15/h (determined by a nasal flow recording method)
  • Have signed the consent document to participate in the study.

Exclusion Criteria:

  • Patients who have been stabilised for less than 10 days (inotropic drugs or modification of the anticipated resynchronisation or PM parameters)
  • Patients who already use sleep disordered breathing devices
  • Resting SBP < 80 mmHg (averaged over 3 separate measurements)
  • Recent angioplasty (within the last 10 days)
  • Infarction within the last 10 days
  • Heart surgery within the last 15 days
  • Valve dysfunction requiring surgery
  • Uncontrolled high blood pressure (BP > 180 and/or 110 mmHg)
  • Anaemia (Hb < 9g/dl)
  • Haemodialysis
  • Patient receiving circulatory assistance
  • Severe chronic respiratory failure (FEV1 < 1000) or hypercapnia greater than 46 mmHg
  • Patient incapable of performing a 6 minute walk test and an exercise test
  • Absolute contraindication for an exercise test and/or physical training according to the recommendations of the French Society of Cardiology
  • Evolving myopericarditis
  • Severe ventricular rhythm disorders that do not stabilise with treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Rehabilitation + Ventilation Group
Patient Heart Failure with sleep disordered breathing who follows ventilation therapy and physical training.

The service provider will provide the patient with the ventilation device and will explain to the patient how to operate the device and how to fit the mask according to the specifications.

There will be an oximetry recording during ventilation on the first night. After the first night, the ventilation parameters recorded by the machine and the oximetry results will be read and used to adjust the settings.

Starting the first week and at the end of the programme, the following ventilation parameters will be collected: compliance, leaks, AHI, ventilation mode, pressures used. The threshold of length of nocturnal ventilation fixed to 3h per night on average in order to consider a compliant patient.

NO_INTERVENTION: Rehabilitation Only Group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peak VO2
Time Frame: Day 1
The primary endpoint is the relative improvement of exercise tolerance, estimated using the changes in the patient's peak VO2 measured before starting and after finishing the rehabilitation programme between the both group.
Day 1
Peak VO2
Time Frame: Between 4 to 9 weeks
The primary endpoint is the relative improvement of exercise tolerance, estimated using the changes in the patient's peak VO2 measured before starting and after finishing the rehabilitation programme between the both group.
Between 4 to 9 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physical training compliance
Time Frame: between 4 and 9 weeks
Secondary endpoints include compliance with rehabilitation sessions, estimated by comparing the number of sessions in which training was effectively carried out with the anticipated number of sessions and other exercise tolerance parameters (maximum power, duration of exercise, submaximal parameters) in each group.
between 4 and 9 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Sonia Corone, MD, Centre Medical de Bligny
  • Principal Investigator: Marie-Christine Iliou, MD, Hôpital Corentin Celton

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2010

Primary Completion (ACTUAL)

June 1, 2014

Study Completion (ACTUAL)

December 1, 2014

Study Registration Dates

First Submitted

May 6, 2010

First Submitted That Met QC Criteria

May 7, 2010

First Posted (ESTIMATE)

May 11, 2010

Study Record Updates

Last Update Posted (ESTIMATE)

March 9, 2015

Last Update Submitted That Met QC Criteria

March 6, 2015

Last Verified

March 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • 2008-07

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.